What happened with BFRG today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Bullfrog AI Holdings, Inc. uses its bfLEAP platform to find patterns in complex biomedical and clinical data for biotechnology and pharmaceutical companies. These analyses help drug developers identify potential targets and patient groups and guide clinical-trial planning. Collaborators can pay cash fees or provide equity or other consideration. Revenue remains limited: its reported collaboration revenue came entirely from one agreement with Eleison Pharmaceuticals, which paid in its own shares rather than cash.
The company also holds licensed drug candidates and plans to use its analysis to guide their development with partners. It aims to transfer drug assets to companies that will commercialize them, rather than sell drugs itself, potentially earning upfront payments, development milestone payments and royalties on drug sales. These programs remain in development; no drug candidate identified by its platform has received approval for commercialization.
The business depends on additional financing, development partners and continued access to licensed technology. Its core bfLEAP technology is licensed from Johns Hopkins University Applied Physics Laboratory under an agreement requiring royalties. Selling or licensing certain drug products also depends on clinical trials and regulatory decisions.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
BullFrog AI’s results hinge on turning its AI platform into paid collaborations: Eleison Pharmaceuticals accounted for all its 2025 revenue, while Sygnature Discovery offers access to additional biopharma clients.
iBio, Inc. faces the same challenge as BullFrog AI: getting partners to pay for AI-assisted drug research, though iBio develops antibodies while BullFrog analyzes biomedical data. Watch whether iBio’s plans to let partners use its discovery platform under license turn into revenue.
AbCellera Biologics Inc. and BullFrog AI both seek fees from drug-development partners and further payments when partnered programs succeed; AbCellera discovers antibodies, while BullFrog analyzes biomedical data. Watch AbCellera’s partnered antibodies reaching the clinic and eventual sales, since it expects most revenue from successful commercialized programs to come from sales royalties, profit shares and commercial milestones.
BioAge Labs, Inc.’s target-discovery collaborations offer a reference for BullFrog AI’s efforts to earn fees from biomedical-data analysis: BioAge uses human datasets to develop drugs, while BullFrog helps partners identify targets and guide drug programs. Watch BioAge’s Novartis collaboration revenue, including upfront payments, milestone payments and research funding, rather than product sales, which it has not generated.
Generate Biomedicines, Inc. shares BullFrog AI’s need to show that computational methods can produce successful drugs: Generate designs protein therapeutics with computer models and experimental testing, while BullFrog uses machine learning for partners and its own drug programs. Generate had no drug approved for sale as of its prospectus, so its protein-drug development progress matters more than model capabilities alone.
BioAge Labs, Inc. earningsBIOA
BioAge Labs, Inc.’s report will show how much collaboration revenue its Novartis work brings in, a test of the partner-fee path BullFrog AI Holdings, Inc. is also pursuing with data analysis.
Read Novartis collaboration revenue alongside what comes from upfront payments, milestones, and research funding. Revenue supported by several types of partner payments would show that drug-program progress can keep a partner paying, a possible route to broader fees for BullFrog’s analysis work; little or no such revenue would show how uneven this model can be without steady customer demand.
Bullfrog AI Holdings, Inc. earningsThis company
Bullfrog AI Holdings, Inc. seeks collaboration fees for biomedical-data analysis, and this report will show whether customers beyond Eleison are paying for its work.
Look at collaboration revenue alongside how many partners have active agreements, and whether the work is being paid for as deliverables are completed. More revenue from multiple partners would show that demand for BullFrog’s data-analysis services is broadening; little revenue or continued reliance on one partner would mean its customer base remains fragile while operations and research still need funding.
